Slideset
View More
Review the latest data on the management of atopic dermatitis from the 2020 AAAAI, AAD, and RAD conferences.
Andrew F. Alexis, MD, MPH
Jonathan Silverberg, MD
Released: September 21, 2020
Following the virtual 2020 American Academy of Dermatology and Revolutionizing Atopic Dermatitis conferences, I describe several of the most clinically relevant data on approved and investigational treatments that have the potential to improve outcomes for our patients.
Andrew F. Alexis, MD, MPH
Physicians:
maximum of 0.5 AMA PRA Category 1 Credits™
Registered Nurses:
0.5 Nursing contact hours
Released: August 10, 2020
Expired:
No longer available for credit
With selective JAK inhibitors currently under investigation for AD, we could see greater efficacy without the safety tradeoffs of broad JAK inhibition.
Jonathan Silverberg, MD
Physicians:
maximum of 0.5 AMA PRA Category 1 Credits™
Registered Nurses:
0.5 Nursing contact hours
Released: August 12, 2020
Expired:
No longer available for credit
Gain expert perspectives on the latest data on the management of atopic dermatitis from the 2020 AAAAI, AAD, and RAD conferences.
Andrew F. Alexis, MD, MPH
Jonathan Silverberg, MD
Physicians:
maximum of 1.0 AMA PRA Category 1 Credit™
Registered Nurses:
1.0 Nursing contact hour
Released: November 5, 2020
Expired:
No longer available for credit
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.